Clinical Trial Update: Precision Recurrence Risk Assessment in Early-stage Hepatocellular Carcinoma

View source ↗

Summary

Tongji Hospital's clinical trial NCT07030842 on precision recurrence risk assessment in early-stage hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Snippet

Sponsor: Tongji Hospital | Conditions: Hepatocellular Carcinoma (HCC) | Status: COMPLETED